Low-level vancomycin resistance in Staphylococcus aureus - An Australian perspective

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 2, 2005, Pages 100-108

  Howden, B P ^a,b   Ward, P B ^a   Johnson, P D R ^a   Charles, P G P ^a   Grayson, M L ^a  

^a AUSTIN HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; AUSTRALIA; BACTERIAL COLONIZATION; BACTERIUM DETECTION; BLEEDING; ENDOCARDITIS; GASTROINTESTINAL TOXICITY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OSTEOMYELITIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AUSTRALIA; HUMANS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 16844371048     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-004-1261-y     Document Type: Review

References (45)

1. Anonymous (2002) Staphylococcus aureus resistant to vancomycin - United States, 2002. Morb Mortal Wkly Rep 51:565-567
2. Anonymous (2002) Vancomycin-resislant Staphylococcus aureus - Pennsylvania, 2002. Morb Mortal Wkly Rep 51:902
3. Anonymous (2004) Vancomycin-resistant Staphylococcus aureus - New York, 2004. Morb Mortal Wkly Rep 53:322-323
4. Ward PB, Johnson PD, Grabsch EA, Mayall BC, Grayson ML (2001) Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med J Aust 175:480-483
5. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP (2001) A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47:399-403
6. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P et al (2004) Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38:521-8
7. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML (2004) Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38:448-451
8. Kaatz GW, Seo SM, Dorman NJ, Lerner SA (1990) Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 162:103-108
9. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135-136
10. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S et al (1997) Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673
11. Hiramatsu K (2001) Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1:147-155
12. Walsh TR, Howe RA (2002) The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Ann Rev Microbiol 56:657-675
13. National Committee for Clinical Laboratory Standards (2004) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Wayne, PA
14. Tenover FC, Biddle JW, Lancaster MV (2001) Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 7:327-332
15. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP (2001) A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47:399-403
16. Sieradzki K, Roberts RB, Haber SW, Tomasz A (1999) The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 340:517-523
17. Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM et al (2003) Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41:5-14
18. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K (1998) Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 42:199-209
19. Sieradzki K, Tomasz A (2003) Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol 185:7103-7110
20. Boyle-Vavra S, Challapalli M, Daum RS (2003) Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin- intermediate resistance. Antimicrob Agents Chemother 47:2036-2039
21. Howe RA, Monk A, Wootton M, Walsh TR, Enright MC (2004) Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis 10:855-857
22. Kuroda M, Kuwahara-Arai K, Hiramatsu K (2000) Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. Biochem Biophys Res Commun 269:485-490
23. Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K (2003) Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol 49:807-821
24. Bischoff M, Roos M, Putnik J, Wada A, Glanzmann P, Giachino P et al (2001) Involvement of multiple genetic loci in Staphylococcus aureus teicoplanin resistance. FEMS Microbiol Lett 194:77-82
25. Mongodin E, Finan J, Climo MW, Rosato A, Gill S, Archer GL (2003) Microarray transcription analysis of clinical Staphylococcus aureus isolates resistant to vancomycin. J Bacteriol 185:4638-4643
26. Ike Y, Arakawa Y, Ma X, Tatewaki K, Nagasawa M, Tomita H et al (2001) Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J Clin Microbiol 39:4445-4451
27. Arakawa Y, Ike Y, Nagasawa M (2004) Where has vancomycin-heterogeneously resistant Staphylococcus aureus gone? Lancet 363:1401
28. Hubert SK, Mohammed JM, Fridkin SK, Gaynes RP, McGowan JE Jr, Tenover FC (1999) Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J Clin Microbiol 37:3590-3593
29. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN et al (2001) Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 32(Suppl 2):S114-S132
30. Howe RA, Noel AR, Bowker KE, Walsh TR, MacGowan AP (2003) The prevalence of heterogenously vancomycin intermediate Staphylococcus aureus (hVISA) in the USA. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. C2-1828
31. Cartolano GL, Cheron M, Benabid D, Leneveu M, Boisivon A (2004) Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect 10:448-451
32. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM et al (2003) Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 36:429-439
33. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA et al (2001) Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 39:2439-2444
34. Tenover FC, Biddle JW, Lancaster MV (2001) Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 7:327-332
35. Wootton M, Avison AB, Bennett PM, Howe RA, Walsh TR (2003) Lack of expression of fmtB/mrp in vancomycin intermediate Staphylococcus aureus (VISA) and hetero (h) VISA phenotype: a new diagnostic marker. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. D-1892
36. Sakoulas G, Eliopoulos GM, Moellering RC Jr, Novick RP, Venkataraman L, Wennersten C et al (2003) Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 187:929-938
37. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr (2004) Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 38:1700-1705
38. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398-2402
39. Pavie J, Lefort A, Ploy MC, Massias L, Chau F, Garry L et al (2003) Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis. Antimicrob Agents Chemother 47:2018-2021
40. Moore MR, Perdreau-Remington F, Chambers HF (2003) Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 47:1262-1266
41. Moise PA, Forrest A, Birmingham MC, Schentag JJ (2002) The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 50:1017-1026
42. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B (2002) Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34:1481-1490
43. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH (2000) Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 46:775-784
44. Ariza J, Pujol M, Cabo J, Pena C, Fernandez N, Linares J et al (1999) Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet. 353:1587-1588
45. Schwaber MJ, Wright SB, Carmeli Y, Venkataraman L, DeGirolami PC, Gramatikova A et al (2003) Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis 9:657-664